FRANKFURT / LONDON (IT BOLTWISE) – The Formycon share showed a slight increase of 0.8 percent in the XETRA session on Tuesday afternoon. The price increase is fueled by positive news from biosimilar development and the settlement of a patent dispute in the USA. Analysts see further potential for the stock as new distribution agreements have been reached for the Eylea biosimilar.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
The Formycon share gained 0.8 percent in the XETRA session on Tuesday afternoon and was quoted at EUR 23.95. This price increase is due to positive developments in the area of biosimilar products. In particular, the settlement of a patent dispute in the USA and new distribution agreements for the Eylea biosimilar have strengthened investor confidence.
Formycon has established itself as a major player in the biosimilars sector in recent years. These biotechnological copycat products offer a cost-effective alternative to expensive original preparations and are becoming increasingly important in the healthcare sector. Recent developments could further strengthen Formycon’s position in the market and open up new growth opportunities.
The price of the Formycon share has fluctuated between EUR 19.18 and EUR 64.40 in the last 52 weeks. The current price is 24.87 percent above the 52-week low, indicating recovery and stabilization. Analysts forecast a medium-term price target of EUR 41.75, which signals further upside potential.
The settlement of the patent dispute in the USA is an important milestone for Formycon. This agreement allows the company to distribute its biosimilar products on the American market without any legal obstacles. In addition, Formycon has concluded a new distribution agreement for the Eylea biosimilar, which should further strengthen its market presence.
A loss of EUR -2.267 per share is expected in the balance sheet for the current year. Nevertheless, experts see positive long-term prospects for the company, particularly due to the increasing acceptance of biosimilars in the healthcare sector. The next quarterly figures are expected on November 13, 2025 and could provide further insights into Formycon’s financial development.
*Order an Amazon credit card with no annual fee with a credit limit of 2,000 euros! a‿z
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Formycon shares on the rise: new developments and market opportunities”.
The post Formycon shares on the rise: new developments and market opportunities appeared first on Veritas News.
